Access to Medicines
- We currently have 290 active programs for launched medicines in markets that have a gross domestic product (GDP) per capita less than Portugal.
- This covers 52 countries.
- Of these, 20 programs cover multiple therapies while the rest are product specific.
- In total, these cover 103 different products in our portfolio.
Access to Medicines Footnotes
Program/commercial transaction defined as a Pfizer or dedicated contract of over $250,000 with a national government or procurement agency, multilateral organization, non-governmental organization (NGO), private institution or aid agency. Represents multi-country initiatives only and does not include numerous local initiatives to address access.
Pfizer Foundation programs represent aggregate investment in program areas with several NGO partners.
As defined by the World Health Organization. Burdens of illness not addressed include road traffic accidents, prematurity and low birth weight and self-inflicted injuries.
Top Ten Medicines and Vaccines by Revenues in 2019
Prevnar® 13 / Prevenar® 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
Norvasc® (amlodipine besylate)
Sutent® (sunitinib malate)
Top Ten Medicines and Vaccines by Revenues in 2019 Footnote
|*Eliquis includes alliance revenues from (Bristol-Myers Squibb) and direct sales.|
Injuries Per 100 Colleagues
Total injury rate in 2019 was 13% lower than in 2018
Progress on Our 2020 Environmental Sustainability Goals2
Greenhouse Gas (GHG) Emissions
Total scope 1 and 2 GHG emissions
In million metric tons CO2EQ
GHG emissions in 2019 were 5% lower than in 2018
2020 Goals vs Baseline
Decrease by 20%
Waste DisposedTotal hazardous and non-hazardous waste in thousand metric tons
Total waste disposed in 2019 was 9% higher than in 2018
Decrease by 15%
2020 Goals vs Baseline:
Water WithdrawalExcluding non-contact cooling water in million cubic meters
Total water withdrawal (excluding non-contact cooling water) in 2019 was 3% lower than in 2018
Decrease by 5%
2020 Goals vs Baseline:
Supply Chain Environmental Sustainability Goal3
|Key suppliers supporting Pfizer's supplier code of conduct||100%||90%||88%||79%|
|Key suppliers aligning with Pharmaceutical Supply Chain Initiative (PSCI) principles||100%||90%||88%||81%|
|Key suppliers managing their environmental impacts||100%||88%||84%||82%|
|Key suppliers with reduction goals for GHG, waste disposal and water withdrawal||90%||49%||52%||41%|
Two serious incidents occurred during work related travel in 2019 that tragically resulted in the deaths of two colleagues. The primary causes of injuries and illnesses recorded in 2019 were ergonomics and slips, trips and falls.
Applies to facilities within Pfizer's operational control as compared with a 2012 baseline. Data are baseline adjusted, reported absolute, using reporting boundaries per theWRI GHG Protocol. The 2012–2018 GHG data were independently verified to the limited assurance level. The verification of the 2019 GHG data will be completed in 2020. While we are on track to exceed our GHG emissions and water goals in 2020 and continue to identify and implement resource reduction projects, we anticipate that we will be unable to sustain achievement of our waste reduction goal due to site expansions and increased production. Through 2020 and beyond we will continue to focus on emission and resource reduction projects. Find more details on our EHS KPIshere.
Key suppliers include 115 major contributors to our external environmental footprint, including suppliers of pharmaceutical ingredients, drug products, raw materials, product packaging services, key research and development collaborators, and freight forwarders. Key suppliers represent only a portion of Pfizer’s overall supply chain for goods and services. Data have been adjusted to reflect the transition of our Consumer Healthcare business.